

# Evidence for cross-talk between M<sub>2</sub> and M<sub>3</sub> muscarinic acetylcholine receptors in the regulation of second messenger and extracellular signal-regulated kinase signalling pathways in Chinese hamster ovary cells

<sup>1,2</sup>David C. Hornigold, <sup>1</sup>Rajendra Mistry, <sup>1</sup>Pamela D. Raymond, <sup>1,3</sup>Jonathan L. Blank & <sup>\*</sup><sup>1</sup>R.A. John Challiss

<sup>1</sup>Department of Cell Physiology and Pharmacology, Maurice Shock Medical Sciences Building, University of Leicester, University Road, Leicester LE1 9HN

**1** We have examined possible mechanisms of cross-talk between the G<sub>q/11</sub>-linked M<sub>3</sub> muscarinic acetylcholine (mACh) receptor and the G<sub>i/o</sub>-linked M<sub>2</sub> mACh receptor by stable receptor coexpression in Chinese hamster ovary (CHO) cells. A number of second messenger (cyclic AMP, Ins(1,4,5)P<sub>3</sub>) and mitogen-activated protein kinase (ERK and JNK) responses stimulated by the mACh receptor agonist methacholine were examined in CHO-m2m3 cells and compared to those stimulated in CHO-m2 and CHO-m3 cell-lines, expressing comparable levels of M<sub>2</sub> or M<sub>3</sub> mACh receptors.

**2** Based on comparisons between cell-lines and pertussis toxin (PTx) pretreatment to eliminate receptor-G<sub>i/o</sub> coupling, evidence was obtained for (i) an M<sub>2</sub> mACh receptor-mediated contribution to the predominantly M<sub>3</sub> mACh receptor-mediated Ins(1,4,5)P<sub>3</sub> response and (ii) a facilitation of the inhibitory effect of M<sub>2</sub> mACh receptor on forskolin-stimulated cyclic AMP accumulation by M<sub>3</sub> mACh receptor coactivation at low agonist concentrations (MCh 10<sup>-9</sup>–10<sup>-6</sup> M).

**3** The most profound cross-talk effects were observed with respect to ERK activation. Thus, while MCh stimulated ERK activation in both CHO-m2 and CHO-m3 cells (pEC<sub>50</sub> values: 5.64 ± 0.09 and 5.57 ± 0.16, respectively), the concentration–effect relation was approx 50-fold left-shifted in CHO-m2m3 cells (pEC<sub>50</sub>: 7.17 ± 0.07). In addition, the ERK response was greater and more sustained in CHO-m2m3 cells. In contrast, only minor differences were seen in the time-courses and concentration-dependencies of JNK activation in CHO-m3 and CHO-m2m3 cells.

**4** Costimulation of endogenous P2Y<sub>2</sub> purinoceptors also caused an approx 10-fold left-shift in the MCh-stimulated ERK response in CHO-m2 cells, suggesting that the G<sub>q/11</sub>/G<sub>i/o</sub> interaction to affect ERK activation is not specific to muscarinic receptors.

**5** PTx pretreatment of cells had unexpected effects on ERK activation by MCh in both CHO-m2m3 and CHO-m3 cells. Thus, in CHO-m3 cells PTx pretreatment caused a marked left-shift in the MCh concentration–effect curve, while in PTx-treated CHO-m2m3 cells the maximal responsiveness was decreased, but the potency of MCh was only slightly affected.

**6** The data presented here strongly suggest that cross-talk between M<sub>2</sub> and M<sub>3</sub> mACh receptors occurs at the level of both second messenger and ERK regulation. Further, these data provide novel insights into the involvement of G<sub>i/o</sub> proteins in both positive and negative modulation of ERK responses evoked by G protein-coupled receptors.

*British Journal of Pharmacology* (2003) **138**, 1340–1350. doi:10.1038/sj.bjp.0705178

**Keywords:** Muscarinic acetylcholine receptor; receptor-G protein coupling; extracellular signal-regulated kinase (ERK); c-Jun N-terminal kinase (JNK); mitogen-activated protein kinase (MAPK); radioligand binding; cyclic AMP; inositol 1,4,5-trisphosphate

**Abbreviations:** CCh, carbachol; CHO, Chinese hamster ovary; ERK, extracellular signal-regulated kinase; GPCR, G protein-coupled receptor; GTP<sub>γ</sub>S, guanosine 5'-[γ-thio]triphosphate; Ins(1,4,5)P<sub>3</sub>, inositol 1,4,5-trisphosphate; JNK, c-Jun N-terminal kinase; mACh, muscarinic acetylcholine; MAPK, mitogen-activated protein kinase; MCh, methacholine; NMS, N-methyl-scopolamine; PLC, phosphoinositide-specific phospholipase C; PTx, pertussis toxin; UTP, uridine 5'-triphosphate

## Introduction

Acetylcholine, as a neurotransmitter, and as a possible non-neuronal mediator (Wessler *et al.*, 1998), exerts many of its actions via interaction with one or more of the five mammalian muscarinic acetylcholine (mACh) receptor subtypes (Bonner *et al.*, 1987; Caulfield & Birdsall, 1998). The mACh receptors can be grouped into two subsets,

\*Author for correspondence; E-mail: jc36@leicester.ac.uk

<sup>2</sup>Current address: BioFocus Discovery Ltd., Unit 10, Cambridge Science Park, Milton Road, Cambridge CB4 3DB

<sup>3</sup>Current address: Millennium Pharmaceuticals Inc., 270 Albany Street, Cambridge, MA 02139, U.S.A.

based on sequence similarities and receptor-G protein-effector coupling preferences (Wess, 1993; Caulfield & Birdsall, 1998). Thus, M<sub>1</sub>, M<sub>3</sub> and M<sub>5</sub> mACh receptors preferentially couple via G<sub>q/11</sub> proteins to the activation of phospholipase C (PLC), while M<sub>2</sub> and M<sub>4</sub> mACh receptors link to downstream effectors via G<sub>i/o</sub> protein activation (e.g. to inhibit adenylyl cyclase). Despite such apparent exclusivity between the signalling pathways activated by M<sub>1</sub>/M<sub>3</sub>/M<sub>5</sub> and M<sub>2</sub>/M<sub>4</sub> mACh receptors, there are many opportunities for 'cross-talk' (Eglen *et al.*, 1994; Challiss & Blank, 1997; Selbie & Hill, 1998). For example, M<sub>2</sub>/M<sub>4</sub> mACh receptors can affect signalling mediated by M<sub>1</sub>/M<sub>3</sub>/M<sub>5</sub> mACh receptors through G<sub>i</sub>-derived βγ-subunit effects on PLCs (Rhee, 2001) or modulate changes in intracellular Ca<sup>2+</sup> concentrations through altering K<sup>+</sup>-conductance (Kurachi, 1995), or activating nonselective cation channels (Zholos & Bolton, 1997; Wang *et al.*, 1999). However, interpretation of potential cross-talk is complicated by the demonstration that M<sub>1</sub>/M<sub>3</sub>/M<sub>5</sub> mACh receptors can also couple to pertussis toxin (PTx)-sensitive G proteins (Offermanns *et al.*, 1994; Akam *et al.*, 2001) and the reported stimulatory effects of M<sub>1</sub> (and M<sub>3</sub>/M<sub>5</sub>) mACh receptors on adenylyl cyclase activity probably result from direct receptor coupling to G<sub>s</sub> proteins (Burford & Nahorski, 1996).

Compelling evidence has accumulated in recent years linking a wide range of G protein-coupled receptors (GPCRs) to the control of mitogen-activated protein kinases (MAPKs) and, as a consequence, the regulation of cell growth and proliferation (Dhanasekaran *et al.*, 1995; Gutkind, 1998; Gudermann *et al.*, 2000). In the case of mACh receptors, activation of MAPK pathways has been demonstrated for both the M<sub>1</sub>/M<sub>3</sub>/M<sub>5</sub> and M<sub>2</sub>/M<sub>4</sub> subfamilies (Winitz *et al.*, 1993; Crespo *et al.*, 1994; Mitchell *et al.*, 1995), suggesting the potential for mACh receptor cross-talk in the regulation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) cascades (Schaeffer & Weber, 1999).

Understanding the mechanisms by which cross-talk between mACh receptors may occur is clearly an important objective, as many cells and tissues express more than one mACh receptor subtype. For example, a wide variety of smooth muscle types express both M<sub>2</sub> and M<sub>3</sub> mACh receptors (see Eglen *et al.*, 1994; 1996) and the respective roles of each subtype have been the subject of much investigation and speculation. The role of the M<sub>3</sub> mACh receptor in smooth muscle contraction is well established (Eglen *et al.*, 1994); however, the role of the usually more abundant M<sub>2</sub> mACh receptor subpopulation is less clear (Eglen *et al.*, 1994; 1996). With respect to the regulation of muscle contraction, pharmacological (Hegde *et al.*, 1997; Sawyer & Ehlert, 1999) and genetic/gene knockout (Matsui *et al.*, 2000; Stengel *et al.*, 2000; 2002) approaches have shown either small direct effects of the M<sub>2</sub> population on contraction or, more commonly, an indirect role through inhibition of the actions of relaxants. To date, very little work has been carried out to analyse the potential for cross-talk between signalling pathways following M<sub>2</sub> and M<sub>3</sub> mACh receptor coactivation.

In the present study we have utilized Chinese hamster ovary (CHO) cells recombinantly expressing M<sub>2</sub> and M<sub>3</sub> mACh receptors, either alone or in combination, to investigate the possible cross-talk between the second messenger-generating and ERK- and JNK-signalling pathways downstream of these receptors.

## Methods

### Materials

*l*-[*N*-methyl-<sup>3</sup>H]-scopolamine (80–85 Ci mmol<sup>-1</sup>), [2,8-<sup>3</sup>H]-cyclic AMP (30–50 Ci mmol<sup>-1</sup>), [*methyl*-<sup>3</sup>H]-thymidine (25 Ci mmol<sup>-1</sup>) and [ $\gamma$ -<sup>32</sup>P]-ATP (3000 Ci mmol<sup>-1</sup>) were obtained from Amersham Biosciences U.K. Ltd. (Little Chalfont, U.K.). Guanosine 5'-( $\gamma$ -thio-[<sup>35</sup>S])triphosphate (1250 Ci mmol<sup>-1</sup>) and D-[inositol-1-<sup>3</sup>H(N)]-1,4,5-trisphosphate (30 Ci mmol<sup>-1</sup>) were obtained from NEN Life Science Products (Zaventem, Belgium). PTx, methacholine (MCh), carbachol (CCh) and forskolin were from Sigma-Aldrich Co. Ltd. (Poole, U.K.). All other reagents were of analytical grade and were obtained from the sources given by Wylie *et al.* (1999) and Akam *et al.* (2001).

### Cell culture and transfection

CHO cell-lines expressing human M<sub>2</sub> (CHO-m2) or M<sub>3</sub> (CHO-m3) mACh receptors were originally obtained from Dr N.J. Buckley (then of the National Institute for Medical Research, Mill Hill, London) and were grown in minimal essential medium (MEM $\alpha$ ) supplemented with newborn calf serum (10%), penicillin (100 U ml<sup>-1</sup>), streptomycin (100  $\mu$ g ml<sup>-1</sup>) and amphotericin B (2.5  $\mu$ g ml<sup>-1</sup>). To generate M<sub>2</sub>/M<sub>3</sub>-coexpressing cell-lines, cDNA encoding the human m3-mACh receptor was inserted into a pCEP4 vector (Invitrogen BV, Groningen, The Netherlands). Low passage CHO-m2 cells were transfected with this plasmid by calcium phosphate–DNA coprecipitation (Sambrook *et al.*, 1989). After 24 h, cells were harvested and seeded into Petri dishes at various cell densities and grown in the constant presence of 400–800  $\mu$ g ml<sup>-1</sup> hygromycin B to select for antibiotic-resistant colonies. Colonies were selected after 21–28 days and expression of M<sub>3</sub> mACh receptor initially assessed by Western blotting using an anti-m3-mACh receptor-specific antibody (Tobin & Nahorski, 1993). M<sub>3</sub> mACh receptor-positive clones were expanded and radioligand binding and Ins(1,4,5)P<sub>3</sub> mass determinations made to verify expression and function of this receptor, while M<sub>2</sub> mACh receptor function was assessed by inhibition of forskolin-stimulated adenylyl cyclase (see below). Based on these criteria, three cell-lines were archived and the B2 clone selected for the most extensive further characterization.

### [<sup>3</sup>H]-NMS saturation and displacement radioligand binding

CHO cell-lines expressing M<sub>2</sub> and/or M<sub>3</sub> mACh receptors were grown to confluence in 175 cm<sup>2</sup> flasks and harvested using HBS–EDTA (10 mM HEPES, 0.9% NaCl, 0.02% EDTA, pH 7.4). A cell-membrane fraction was then prepared by homogenization and centrifugation, and [<sup>3</sup>H]-NMS saturation binding performed as described previously (Burford & Nahorski, 1996; Akam *et al.*, 2001), except that GTP was omitted and membranes were incubated with the radioligand for 90 min at 37°C before separating bound and free fractions by rapid vacuum filtration. Nonspecific binding was defined in the presence of 1  $\mu$ M atropine. Displacement analysis for triptamine was performed using approx 0.8 nM [<sup>3</sup>H]-NMS and a wide range of antagonist concentrations (0.1 nM–100  $\mu$ M); again incubations were for 90 min at 37°C.

*[<sup>35</sup>S]-GTPγS binding and G<sub>q</sub>α immunoprecipitation*

Membranes prepared from CHO-m2, -m3 and -m2m3 cells were incubated with approx 1 nM [<sup>35</sup>S]-GTPγS in a buffer containing 100 mM NaCl, 1 μM GDP±agonist for 2 min at 30°C. Residual binding in the presence of 10 μM GTPγS was considered nonspecific (NSB) and subtracted from basal and agonist-stimulated total counts. Incubations were terminated, membranes solubilized and G proteins immunoprecipitated using an 'in-house' G<sub>q</sub>α-specific antibody (raised against the C-terminal sequence CLQLNLKEYNLV) exactly as described previously by Akam *et al.* (2001). Scintillation fluid was added to thoroughly washed protein A-sepharose-G<sub>q</sub>α-[<sup>35</sup>S]-GTPγS complexes and radioactivity determined.

*Incubation methods and Ins(1,4,5)P<sub>3</sub> and cyclic AMP determination*

For experiments in intact cells, the different CHO cell-lines were grown to confluence in 24-well multiwells. Where cells were pretreated with PTx, it was added (100 ng ml<sup>-1</sup>) for 20–24 h before experimentation. For all experiments, monolayers were washed with HEPES-buffered Krebs–Henseleit buffer (KHB: composition in mM: NaCl, 118; KCl, 4.7; NaHCO<sub>3</sub>, 25; MgSO<sub>4</sub>, 1.2; NaH<sub>2</sub>PO<sub>4</sub>, 1.2, CaCl<sub>2</sub>, 1.3; D-glucose, 11; HEPES, 10; pH 7.4 after equilibration with O<sub>2</sub>/CO<sub>2</sub> 95:5). Cells were challenged with the concentrations of agonists, and for the times indicated in the Results section. Incubations were terminated by aspiration and rapid addition of 250 μl ice-cold 0.5 M trichloroacetic acid (TCA) and transferal of the multiwell plate to an icebath. After extraction for 30 min, TCA extracts were collected and neutralized using tri-*n*-octylamine/freon (Challiss *et al.*, 1988). Cyclic AMP and Ins(1,4,5)P<sub>3</sub> were determined using the radioreceptor assays of Brown *et al.* (1971) and Challiss *et al.* (1988), respectively.

*ERK and JNK activity determinations*

CHO-m2, -m3 or -m2m3 cells were grown in six-well plates. Where cells were pretreated with PTx, it was added (100 ng ml<sup>-1</sup>) for 20–24 h before experimentation. Incubations were performed in KHB as described above. Incubations were terminated by aspiration and washing each well with ice-cold phosphate-buffered saline. Cells were processed for ERK and JNK assay exactly as described previously (Wylie *et al.*, 1999) with 200 μl (ERK) and/or 400 μl (JNK) aliquots of supernatant being taken for subsequent activity assays. ERK proteins were immunoprecipitated and activity assays performed exactly as described previously (Wylie *et al.*, 1999). GST-c-Jun beads were prepared and used to determine JNK activity exactly as previously described (Wylie *et al.*, 1999).

*Data analysis*

All data are presented as means ± s.e. mean for the indicated number of separate experiments performed with the indicated individual experiment replication. Radioligand binding data and agonist/antagonist concentration–effect curves were analysed using a commercially available program (GraphPad Prism version 3.0; GraphPad Software, San Diego, CA, U.S.A.). Where responses to MCh were biphasic (see cyclic AMP data), concentration–response relations were fitted by a

sum of two logistic equations:

$$f = I_{\max} + F_s \left\{ 1 - \frac{c^{n_1}}{c^{n_1} + K_1^{n_1}} \right\} + S_{\max} \left\{ \frac{c^{n_2}}{c^{n_2} + K_2^{n_2}} \right\}$$

where  $I_{\max}$  is the maximum inhibition of the forskolin-stimulated adenylyl cyclase activity by MCh ( $F_s$ ) with IC<sub>50</sub> value  $K_1$  and Hill coefficient  $n_1$ ;  $S_{\max}$  is the maximum stimulation of cAMP accumulation by high concentrations of MCh with EC<sub>50</sub> value and Hill coefficient  $K_2$  and  $n_2$ , respectively, and  $c$  is the concentration of MCh. Fitting was done by least-squares minimization using the above equation and GraphPad Prism (version 3.0).

Statistical differences between datasets were assessed by one-way analysis of variance followed by Duncan's multiple-range test at  $P < 0.05$  using SPSS (version 10, SPSS, Chicago, IL, U.S.A.).

**Results***Establishing CHO-m2m3 cell-lines*

CHO cells stably expressing M<sub>2</sub> mACh receptors (CHO-m2;  $B_{\max}$  858 ± 51 pmol mg<sup>-1</sup> protein) were transfected with a plasmid encoding the M<sub>3</sub> mACh receptor. Hygromycin-resistant clones were initially assessed by Western blotting using a M<sub>3</sub>-specific antibody (Tobin & Nahorski, 1993) and cells expressing M<sub>3</sub> mACh receptor immunoreactivity screened for second messenger responses by assessing the ability of MCh to stimulate Ins(1,4,5)P<sub>3</sub> generation and inhibit forskolin-stimulated cyclic AMP accumulation. Two cell-lines (termed B2 and B7) emerged from this screening and were evaluated for total mACh receptor expression by performing [<sup>3</sup>H]-NMS binding on suspensions of intact cells. In addition, to subdivide the M<sub>2</sub>/M<sub>3</sub> subpopulations in B2 and B7 cell-lines, displacement of specific [<sup>3</sup>H]-NMS binding from membranes by the highly M<sub>2</sub>-selective antagonist tripitramine (Melchiorre *et al.*, 1993) was assessed. [<sup>3</sup>H]-NMS displacement analysis in membranes derived from CHO-m2 and CHO-m3 cells demonstrated tripitramine to be highly discriminating (approx 400 fold) between M<sub>2</sub> (pK<sub>i</sub> 9.4) and M<sub>3</sub> (pK<sub>i</sub> 6.8) mACh receptors. The results of these binding studies are summarized in Table 1. It can be seen that for both the B2 and B7 cell-lines there is an approx 3 : 1 M<sub>3</sub> : M<sub>2</sub> ratio. The CHO-m2m3 B2 cell-line was selected for further study. Key findings of this study were reproduced in the B7 cell-line to provide evidence against clonal variation underlying any of the observed effects.


*[<sup>35</sup>S]-GTPγS binding and G<sub>q</sub>α-subunit-selective immunoprecipitation to assess receptor–G<sub>q11</sub> coupling*

Receptor coupling to G<sub>q</sub> proteins was initially investigated in membranes prepared from CHO-m2, -m3 or -m2m3 (B2) cell-lines by [<sup>35</sup>S]-GTPγS binding and subsequent immunoprecipitation using a G<sub>q</sub>α-specific antibody (Akam *et al.*, 2001). Membranes prepared from CHO-m3, but not -m2 cells showed robust agonist-stimulated increases in [<sup>35</sup>S]-GTPγS associated with immunoprecipitated G<sub>q</sub>α (Figure 1). A comparable increase in [<sup>35</sup>S]-GTPγS binding to G<sub>q</sub>α was observed in CHO-m2m3 membranes and MCh stimulated this response with similar potencies in the two preparations (pEC<sub>50</sub> values: CHO-m3, 4.49 ± 0.34; CHO-m2m3, 4.29 ± 0.37). PTx pretreat-

**Table 1** Assessment of receptor expression levels in CHO-m2, -m3 and -m2m3 cell-lines by [<sup>3</sup>H]-NMS saturation binding and quantitation of M<sub>2</sub> and M<sub>3</sub> mACh receptor subpopulations in B2 and B7 clones

Cell-line	$B_{max}$ (pmol mg <sup>-1</sup> protein)	Ratio M <sub>2</sub> : M <sub>3</sub>	No. expts. (n)
CHO-m2	0.86 ± 0.05	100 : 0	4
CHO-m3	1.48 ± 0.12	0 : 100	4
CHO-m2m3 (B2)	2.16 ± 0.21	27 : 73	6
CHO-m2m3 (B7)	2.28 ± 0.26	30 : 70	3

$B_{max}$  values are expressed as means ± s.e. mean for the indicated number (n) of experiments. M<sub>2</sub>:M<sub>3</sub> ratios were determined by two-site analysis (GraphPad Prism) of triptamine displacement isotherms for a single concentration of [<sup>3</sup>H]-NMS (approx 0.8 nM).



**Figure 1** Effects of PTx pretreatment on basal and MCh-stimulated [<sup>35</sup>S]-GTP $\gamma$ S binding to G<sub>q/11 $\alpha$</sub>  in membranes prepared from CHO-m2, -m3 and -m2m3 cells. CHO cells were preincubated in the presence of PTx (100 ng ml<sup>-1</sup>; 24 h) or vehicle before preparation of membranes. MCh (1 mM) or buffer additions to membranes were for 2 min at 30°C and, following solubilization, [<sup>35</sup>S]-GTP $\gamma$ S-G<sub>q/11 $\alpha$</sub>  complexes were immunoprecipitated and radioactivity assessed as described in the Methods section. Data are shown as means ± s.e. mean for four separate experiments performed in duplicate. For both CHO-m3 and CHO-m2m3 membranes, a significant (\**P* < 0.05) increase in G<sub>q/11 $\alpha$</sub> -associated [<sup>35</sup>S]-GTP $\gamma$ S binding was stimulated by MCh irrespective of PTx pretreatment. In addition, following PTx pretreatment a greater agonist-stimulated G<sub>q/11 $\alpha$</sub> -[<sup>35</sup>S]-GTP $\gamma$ S binding was observed (#*P* < 0.05) in CHO-m2m3, but not CHO-m2 or -m3 membranes.

ment prior to membrane preparation only appeared to affect receptor-G protein coupling in the case of the CHO-m2m3 cell-line. Thus, MCh stimulated an approx 70% greater accumulation of [<sup>35</sup>S]-GTP $\gamma$ S-G<sub>q $\alpha$</sub>  complexes in membranes prepared from PTx pretreated CHO-m2m3 cells (Figure 1), despite the increase in  $E_{max}$ , the potency of MCh was similar in PTx-treated M<sub>3</sub>-expressing cell-lines (pEC<sub>50</sub> values: CHO-m3, 4.29 ± 0.31; CHO-m2m3, 4.20 ± 0.14).

#### Comparison of Ins(1,4,5)P<sub>3</sub> responses in CHO-m2, -m3 and -m2m3 cell-lines

MCh (1 mM) stimulated robust increases in Ins(1,4,5)P<sub>3</sub> accumulation in the CHO-m3 and -m2m3 cell-lines (Figure 2a), but not in CHO-m2 cells where no agonist-stimulated increase in this second messenger was observed. As can be seen in Figure 2, the amplitude of the increase in Ins(1,4,5)P<sub>3</sub> accumulation was greater in the CHO-m2m3 cell-line, with both a greater peak (25 ± 9%) and plateau response


being consistently observed. Examination of the concentration-dependency of the initial peak response (at 15 s; Figure 2b) confirmed the greater peak increase in Ins(1,4,5)P<sub>3</sub> in the CHO-m2m3 cell-line and also demonstrated a three-fold decrease in the EC<sub>50</sub> value in this cell-line (pEC<sub>50</sub> values: CHO-m3, 5.21 ± 0.10; CHO-m2m3, 5.67 ± 0.11; *P* < 0.05). As we have shown previously (Wylie *et al.*, 1999) PTx pretreatment of CHO-m3 cells had no effect on either the time-course (data not shown) or concentration-dependency of Ins(1,4,5)P<sub>3</sub> accumulation (Figure 2c). Interestingly, PTx treatment of CHO-m2m3 cells did affect the Ins(1,4,5)P<sub>3</sub> response, generating  $E_{max}$  and EC<sub>50</sub> values in this cell-line that were indistinguishable from those obtained in control CHO-m3 cells (Figure 2d).

#### Effects of PTx pretreatment on basal and agonist-stimulated cyclic AMP responses in CHO-m2m3 cells

MCh (1 mM) stimulated a robust (eight-fold) increase in cyclic AMP accumulation in CHO-m2m3 cells and PTx pretreatment affected this second messenger response (Figure 3a). Thus, the cyclic AMP response to MCh was approx two-fold greater in PTx pretreated CHO-m2m3 cells, without a change in the concentration-dependency assessed at the 5 min peak (pEC<sub>50</sub> values: -PTx, 4.24 ± 0.22; +PTx, 4.38 ± 0.19; Figure 3b). The data shown in Figures 2 and 3 provide evidence consistent with a M<sub>2</sub> mACh receptor-G<sub>i</sub> modulation of both Ins(1,4,5)P<sub>3</sub> and cyclic AMP responses in the CHO-m2m3 cell-line.

#### Modulatory effects of mACh receptor activation on forskolin-stimulated adenylyl cyclase activity in CHO-m2, -m3 and -m2m3 cells

The adenylyl cyclase activator forskolin (10 μM) stimulated comparable, large (> 100 fold) increases in cyclic AMP accumulations in CHO-m2, -m3 and -m2m3 cell-lines. The effects of increasing concentrations of MCh on forskolin-stimulated cyclic AMP responses in CHO-m2, -m3 and -m2m3 cells are shown in Figure 4. In CHO-m2 cells, MCh concentration-dependently inhibited forskolin-stimulated cyclic AMP accumulation (pIC<sub>50</sub>: 6.60 ± 0.06) with a maximally effective concentration of agonist causing a > 90% inhibition. In both CHO-m3 and -m2m3 cells, a biphasic modulation of forskolin-stimulated adenylyl cyclase activity by MCh was observed (Figure 4). At low agonist concentrations, inhibitory effects were observed that were maximal between 0.1 and 1 μM MCh for both cell-lines, whereas at higher MCh concentrations this effect was superseded by an enhancement of the



**Figure 2** Comparison of time- and concentration-dependent agonist-stimulated Ins(1,4,5)P<sub>3</sub> accumulations in CHO-m3 and -m2m3 cells. Cell monolayers were stimulated with either MCh (1 mM) for the times indicated (a), or for 15 s with different concentrations of MCh (b). CHO-m3 (c) or CHO-m2m3 (d) cells were pretreated with PTx (100 ng ml<sup>-1</sup>, 24 h) or vehicle before challenge with the indicated concentrations of MCh for 15 s. Incubations were terminated and extracts prepared for Ins(1,4,5)P<sub>3</sub> mass determination as described in the Methods section. Data are shown as means  $\pm$  s.e. mean for three (panels a and c) or four (panels b and d) separate experiments performed in duplicate.

forskolin response. Although the modulatory effects of MCh were similar in the CHO-m3 and -m2m3 cell-lines, subtle differences could be observed. Thus, analysis of the curves (using the equation given in the Methods) revealed that  $K_1$  values (see Data analysis section for  $K_1$  definition) for MCh-mediated inhibitions were  $22 \pm 5$  versus  $38 \pm 5$  nM in CHO-m2m3 and -m3 cells, respectively, and MCh caused a significantly greater maximum inhibitory effect ( $66 \pm 3\%$  versus  $42 \pm 4\%$ ;  $P < 0.05$ ) in CHO-m2m3 compared to CHO-m3 cells over the  $10^{-9}$ – $10^{-6}$  M concentration range (see Figure 4 inset).


Further evidence that both M<sub>2</sub> and M<sub>3</sub> mACh receptors shape the modulatory effects of MCh on forskolin-stimulated adenylyl cyclase activity in the CHO-m2m3 cell-line is provided in Figure 5. Thus, while PTx treatment of CHO-m3 cells has no significant effect on the MCh modulation of cyclic AMP levels, a marked attenuation of the inhibitory effect seen at low MCh concentrations was observed in the CHO-m2m3 cell-line (Figure 5). These data together strongly suggest that M<sub>2</sub> and M<sub>3</sub> mACh receptors cooperate in the regulation of adenylyl cyclase activity at low agonist concentrations, whereas at high agonist concentration the adenylyl cyclase stimulatory effect mediated by the M<sub>3</sub> mACh receptor predominates.

#### *Time- and concentration-dependent effects of M<sub>2</sub> and M<sub>3</sub> mACh receptor stimulation on ERK and JNK activities*

MCh stimulation of CHO-m2 and -m3 cells resulted in rapid, robust (15–20 fold-over-basal) increases in ERK activity that peaked at 5 min and had returned to close to basal levels within 30 min (Figure 6a). The stimulatory effect of MCh was

concentration-dependent (assessed at 5 min) generating EC<sub>50</sub> values of 2–3  $\mu$ M for each cell-line (pEC<sub>50</sub> values: CHO-m2,  $5.64 \pm 0.09$ ; CHO-m3,  $5.57 \pm 0.16$ ; Figure 6b). Strikingly, two potentially important differences were observed in the CHO-m2m3 cell-line. Firstly, the magnitude of the ERK response was greater and the increase in activity sustained over a longer period (Figure 6a). Thus, whereas ERK activity had returned to close to basal levels in CHO-m2 and -m3 cells ( $2.4 \pm 0.4$  and  $2.5 \pm 0.6$ -fold-over-basal, respectively) after 30 min exposure to agonist, it was still substantially elevated in CHO-m2m3 cells ( $8.2 \pm 0.8$ -fold-over-basal;  $P < 0.05$  compared to CHO-m2 and -m3 cells, Figure 6a). Secondly, the concentration–effect curve for ERK activation by MCh was >25-fold left-shifted (pEC<sub>50</sub>:  $7.17 \pm 0.07$ ;  $P < 0.05$  compared to CHO-m2 and -m3 cells, Figure 6b). These key differences were also seen in parallel experiments using the CHO-m2m3 B7 clone (data not shown).

With respect to JNK activity, MCh addition to CHO-m2 cells failed to cause a reproducible increase in the activity of this MAPK, whereas stimulation of CHO-m3 and -m2m3 cells produced time- and concentration-dependent increases in JNK activity (Figure 7). MCh stimulated similar maximal five to six-fold increases in JNK activity in both CHO-m3 and -m2m3 cells at 45 min after agonist addition, although basal JNK activity was consistently higher in the coexpressing cell-line (CHO-m3,  $1.01 \pm 0.38$ ; CHO-m2m3,  $2.25 \pm 0.05$  pmol phosphate incorporated into c-Jun min<sup>-1</sup> mg<sup>-1</sup> protein;  $P < 0.05$ ). The concentration-dependency of JNK activation by MCh was 2.5-fold left-shifted in the coexpressing cell-line (pEC<sub>50</sub> values: CHO-m3,  $6.11 \pm 0.11$ ; CHO-m2m3,  $6.55 \pm 0.13$ ;  $P < 0.05$ ) compared to the >25-fold shift noted for ERK activation in the coexpressing cell-line.




**Figure 3** Effects of PTx pretreatment on time- and concentration-dependencies of MCh-stimulated cyclic AMP accumulations in CHO-m2m3 cells. CHO-m2m3 cell monolayers were pretreated with PTx (100 ng ml<sup>-1</sup>, 24 h) or vehicle before challenge with either 1 mM MCh for the times indicated (a), or with different concentrations of MCh for 5 min (b). Incubations were terminated and extracts prepared for cyclic AMP mass determination as described in the Methods section. Data are shown as means  $\pm$  s.e. mean for three separate experiments performed in duplicate.

#### Coactivation of P2Y and M<sub>2</sub> mACh receptors also facilitates ERK activation

CHO cells possess endogenous P2Y<sub>2</sub> purinoceptors that can mediate an ERK response (Dickenson *et al.*, 1998). This G<sub>q/11</sub>-coupled receptor caused a modest concentration-dependent increase in ERK activity in the CHO-m2 cell-line (pEC<sub>50</sub>: 5.40  $\pm$  0.34; E<sub>max</sub>, 5.0  $\pm$  0.5-fold-over-basal) in response to UTP (Figure 8 inset). Stimulation of CHO-m2 cells with MCh in the presence of UTP (10  $\mu$ M) produced a concentration-effect curve for ERK activation, which was approx 10-fold left-shifted (pEC<sub>50</sub> values: -UTP, 5.53  $\pm$  0.24; +UTP, 6.51  $\pm$  0.31;  $P < 0.05$ ) without significantly affecting the maximal response (Figure 8). Thus, both the native UTP receptor and recombinant M<sub>3</sub> mACh receptor increase the apparent potency of MCh at the M<sub>2</sub> mACh receptor to cause ERK activation.

#### Effects of PTx on the concentration-dependent activation of ERK by MCh in CHO-m2, -m3 and -m2m3 cells

The robust ERK activation stimulated by incubation of CHO-m2 cells with MCh (100  $\mu$ M) for 5 min was completely




**Figure 4** Effects of M<sub>2</sub> and/or M<sub>3</sub> mACh receptor activation on forskolin-stimulated cyclic AMP accumulations in CHO-m2, -m3 and -m2m3 cells. The indicated concentrations of MCh were added to cell monolayers for 10 min before challenge with forskolin (10  $\mu$ M). After a further period of 10 min incubations were terminated and cyclic AMP mass determined as described in the Methods section. Data are shown as means  $\pm$  s.e. mean for three (CHO-m2) or four (CHO-m3 and -m2m3) separate experiments performed in duplicate. The inset focuses on the inhibitory effects of 10<sup>-9</sup>–10<sup>-6</sup> M MCh in the three cell-lines.

abolished by PTx pretreatment (Figure 9a). Therefore, it was anticipated that PTx pretreatment would result in a purely M<sub>3</sub> mACh receptor–G<sub>q/11</sub>-mediated ERK activation in CHO-m2m3 cells. As can be seen in Figure 9b, PTx treatment caused a marked decrease in the maximal ERK activation elicited by MCh, and a leftward shift in the concentration-dependency (pEC<sub>50</sub> values: -PTx, 7.04  $\pm$  0.13; +PTx, 7.68  $\pm$  0.18;  $P < 0.05$ ). In the light of this unexpected result, the effect of PTx pretreatment on the agonist-stimulated ERK response in CHO-m3 cells was also investigated. As can be seen in Figure 9c, PTx pretreatment of CHO-m3 cells caused a marked (>50-fold) leftward shift in the concentration-dependency of ERK activation by MCh (pEC<sub>50</sub> values: -PTx,  $\pm$  0.16; +PTx, 7.88  $\pm$  0.29;  $P < 0.05$ ).

## Discussion


Although it is clear that in some cases signal transduction can be viewed as a series of parallel signalling pathways, activated by specific subsets of receptors that bring about distinct cellular responses, there is also considerable evidence for 'cross-talk' between signalling pathways (Gudermann *et al.*, 1996; Selbie & Hill, 1998; Schaefer & Weber, 1999). Indeed, the apparent overlap between the signalling pathways activated by different extracellular stimuli can sometimes be perplexing (see Pawson & Saxton, 1999). Nevertheless, it is becoming increasingly clear that the intracellular milieu is a highly structured environment and unwanted cross-talk is efficiently eliminated *in vivo* by preventing the components of the different pathways from coming into intimate contact through compartmentation and/or the 'scaffolding' of signalling complexes (Gudermann *et al.*, 1996; Burack & Shaw, 2000;



**Figure 5** Effects of PTx pretreatment on the concentration-dependent modulatory actions of MCh on forskolin-stimulated cyclic AMP accumulations in CHO-m3 and -m2m3 cells. (a) CHO-m3 and (b) CHO-m2m3 cell monolayers were pretreated with PTx (100 ng ml<sup>-1</sup>, 24 h) or vehicle before challenge with the indicated concentrations of MCh for 10 min before addition of forskolin (10 μM). After a further period of 10 min, incubations were terminated and cyclic AMP mass determined as described in the Methods section. Results are expressed relative to the cyclic AMP responses to forskolin alone (CHO-m3: -PTx, 1008 ± 41; +PTx, 433 ± 50; CHO-m2m3: -PTx, 908 ± 110; +PTx, 526 ± 51 pmol mg<sup>-1</sup> protein), which are set to 100% for each condition. Data are shown as means ± s.e. mean for four (CHO-m3) or five (CHO-m2m3) separate experiments performed in duplicate. PTx did not significantly affect the modulatory effect of MCh in CHO-m3 cells, but significant differences were seen in toxin-treated CHO-m2m3 cells (\**P* < 0.05).

Dumont *et al.*, 2002). However, a number of physiologically important processes have been shown to depend upon cross-talk between pathways activated by distinct receptors to bring about phenomena such as coincidence detection (Sunahara *et al.*, 1996; Batchelor & Garthwaite, 1997; Sweatt, 2001).

In the present study, we have investigated whether cross-talk occurs between the pathways that lie downstream of M<sub>2</sub> and M<sub>3</sub> mACh receptors stably coexpressed in CHO cell-lines. The clones isolated in this study, which demonstrated a coexpression of these receptor populations, both exhibited M<sub>3</sub> > M<sub>2</sub>




**Figure 6** Time- and concentration-dependent increases in extra-cellular signal-regulated kinase (ERK) activity stimulated by MCh in CHO-m2, -m3 and -m2m3 cells. (a) Confluent monolayers of CHO cells were stimulated with MCh (100 μM) for the times indicated, (b) or with different concentrations of MCh for 5 min. Incubations were terminated, cell lysates prepared and kinase assays performed as described in the Methods section. Data are expressed as either a 'fold' increase over basal ERK activity (a) or as an enzymic activity (expressed as fmol phosphate incorporated into the EGF receptor fragment substrate per min per mg of cell protein) (b). Data are presented as means ± s.e. mean for four to eight separate experiments (panel a), or, for data shown in panel b, four (CHO-m2), five (CHO-m3) or six (CHO-m2m3) separate experiments.


mACh receptor densities (see Table 1). While this differs from the situation in a number of tissues, for example, the majority of smooth muscle types where the M<sub>2</sub> mACh receptor predominates, it does reflect the receptor distributions in some tissues (e.g. rat uterine smooth muscle; Choppin *et al.*, 1999), and we considered that the CHO-m2m3 cell-lines we had isolated and characterized should provide useful information on mACh receptor cross-talk at multiple loci downstream of receptor activation.

#### Cross-talk at the level of second messenger generation

In both the CHO-m2m3 and -m3 cell-lines, but not in CHO-m2 cells, MCh addition caused a rapid and large increase in Ins(1,4,5)P<sub>3</sub>. In the coexpressing cell-line, the initial peak




**Figure 7** Concentration-dependent increases in c-Jun N-terminal kinase (JNK) activity stimulated by MCh in CHO-m3 and -m2m3 cells. Confluent monolayers of CHO cells were stimulated with the indicated concentrations of MCh for 30 min. Incubations were then terminated, cell lysates prepared and JNK assays performed as described in the Methods section. Data are expressed as enzymic activities (expressed as fmol phosphate incorporated into c-Jun fusion protein per min per mg of cell protein) and represent means  $\pm$  s.e. mean for four (CHO-m3) or six (CHO-m2m3) separate experiments. The inset shows a representative experiment to illustrate a typical time-course of MCh (100  $\mu$ M)-stimulated JNK activation in the two cell-lines.



**Figure 8** Effects of coincident P2Y/M<sub>2</sub> receptor stimulation on ERK activity in CHO-m2 cells. Confluent CHO-m2 monolayers were challenged with the indicated concentrations of MCh in the absence or presence of UTP (10  $\mu$ M) for 5 min. Incubations were terminated, cell lysates prepared and kinase assays performed as described in the Methods section. Data are expressed as a 'fold' increase over basal ERK activity and are presented as means  $\pm$  s.e. mean for three separate experiments. The inset shows the concentration-dependency of ERK activation by UTP ( $n=3$  for all data, except 300  $\mu$ M UTP point where  $n=2$ ).

increase in Ins(1,4,5)P<sub>3</sub> was greater, and the concentration-dependency was approx three-fold to the left of the responses seen in CHO-m3 cells expressing a comparable M<sub>3</sub> mACh receptor density. Furthermore, elimination of productive



**Figure 9** Effects of PTx pretreatment on the concentration-dependencies of ERK activation by MCh in CHO-m2, -m3 and -m2m3 cells. (a) CHO-m2, (b) CHO-m2m3 and (c) CHO-m3 cell monolayers were pretreated with PTx (100 ng ml<sup>-1</sup>, 24 h) or vehicle before challenge with the indicated concentrations of MCh (panel a; 100  $\mu$ M). Incubations were terminated, cell lysates prepared and kinase assays performed as described in the Methods section. Data are expressed either as a 'fold' increase over basal ERK activity (panels a and b), or as a percentage of the response to 100  $\mu$ M MCh in vehicle-treated CHO-m3 cells (panel c). In all cases, data are shown as means  $\pm$  s.e. mean for at least three separate experiments.

coupling to cellular G<sub>i/o</sub> proteins in CHO-m2m3 cells decreased both the peak response and shifted the concentration-dependency to that seen in CHO-m3 cells. These data strongly suggest that in the CHO-m2m3 cell-line, agonist



stimulation of the M<sub>2</sub> mACh receptor facilitates the M<sub>3</sub>-driven Ins(1,4,5)P<sub>3</sub> response. Such an effect might be brought about by a number of mechanisms, including a G<sub>i</sub>-derived βγ subunit activation of PLC-β isoenzymes that is not observed with M<sub>2</sub> mACh receptor activation alone as the effect may be conditional upon a G<sub>q/11α</sub>–PLC-β binding interaction (Chan *et al.*, 2000). Alternatively, the liberation of βγ subunits through M<sub>2</sub> mACh receptor activation may facilitate G<sub>q/11α</sub>-mediated signalling by increasing the efficiency of G<sub>q/11</sub> heterotrimer presentation to the activated M<sub>3</sub> mACh receptor (Quitterer & Lohse, 1999). A further possibility is that the enhanced response seen in CHO-m2m3 cells might be mediated through an M<sub>2</sub>-mediated enhancement of a Ca<sup>2+</sup> entry pathway to facilitate phospholipase C isoenzymic activities (Rhee, 2001). However, our preliminary data on MCh-stimulated [Ca<sup>2+</sup>]<sub>i</sub> responses in the CHO-m3 and CHO-m2m3 cell lines have provided no evidence in support of this possibility (Hornigold, D.C., Daniels, D. & Challiss, R.A.J., unpublished data).

As well as stimulating Ins(1,4,5)P<sub>3</sub> accumulation, M<sub>3</sub> mACh receptor activation also increased cyclic AMP accumulation by a mechanism that was attenuated by M<sub>2</sub> mACh receptor coactivation. Thus, PTx pretreatment of CHO-m2m3 cells resulted in a marked increase (by approx 100%) in peak cyclic AMP accumulation without affecting the concentration-dependency of this effect. Under conditions where basal cyclic AMP accumulation was increased by forskolin a rather different picture emerged. Thus, while agonist stimulation of M<sub>2</sub> mACh receptors resulted in a monophasic inhibition of the forskolin-stimulated response, M<sub>3</sub> receptor activation caused a biphasic response where low concentrations of MCh caused an inhibition, which was superseded by an enhancement of the forskolin-stimulated accumulation at higher agonist concentrations. In experiments not reported here, it has been shown that the inhibitory effect of MCh in CHO-m3 cells is dependent on the presence of extracellular Ca<sup>2+</sup> and is blocked by lanthanides (La<sup>3+</sup> and Gd<sup>3+</sup>). These and other data suggest that receptor-gated and/or store-depletion-operated Ca<sup>2+</sup>-channels cause Ca<sup>2+</sup> entry that inhibits specific adenylyl cyclase (AC5/AC6) isoenzymes in CHO cells, a mechanism observed previously in other cell-types (Fagan *et al.*, 1998; Wong *et al.*, 2000). Irrespective of the mechanisms underlying the biphasic cyclic AMP response seen in CHO-m3 cells, an interaction between M<sub>2</sub>- and M<sub>3</sub>-mediated mechanisms to inhibit forskolin-stimulated adenylyl cyclase activity was clearly evident at low (≤1 μM) MCh concentrations. This was confirmed by the demonstration that following PTx pretreatment, the magnitude and concentration-dependency of the inhibitory effects of MCh in CHO-m2m3 cells were similar to those seen in CHO-m3 cells.

#### Cross-talk at the level of the MAP kinases

In CHO cells, stimulation of M<sub>2</sub> and M<sub>3</sub> mACh receptors caused comparable activations of ERK, whereas JNK activity was activated only by M<sub>3</sub> mACh receptors, in agreement with previous work (Wylie *et al.*, 1999). The pathways linking M<sub>2</sub>/M<sub>3</sub> mACh receptor activation to ERK have been investigated in CHO and other cell-types. Such studies have often shown the dependence of the M<sub>3</sub>-driven response on PKC and possibly other intermediary proteins (Kim *et al.*, 1999; Wylie *et al.*, 1999; Slack, 2000; Budd *et al.*, 2001), while the

M<sub>2</sub>-driven ERK response has been proposed to be Gβγ-dependent and may involve pathways distinct from, or overlapping with those seen following M<sub>3</sub> mACh receptor activation (Winitz *et al.*, 1993; Crespo *et al.*, 1994; Lopez-Illasaca *et al.*, 1997; Wylie *et al.*, 1999). In the CHO-m2m3 cell-lines, the concentration-dependency of ERK activation by MCh was dramatically left-shifted (by more than 25-fold), the maximal ERK response increased, and the duration of the ERK activation prolonged, compared to the MCh responses observed in either CHO-m2 or -m3 cells. The M<sub>2</sub>/M<sub>3</sub> synergism, at least with respect to the sensitivity increase for ERK activation, is unlikely to be specific to these mACh receptor subtypes, but a more general consequence of coactivating G<sub>q/11</sub>- and G<sub>i/o</sub>-coupled GPCRs, as activation of endogenous P2Y receptors in CHO-m2 cells also caused a significant leftward shift in the MCh concentration–effect curve for ERK activation. However, the presence of G<sub>q/11</sub>- and G<sub>i/o</sub>-coupled GPCRs responsive to a common hormone/neurotransmitter may optimize the synergism. In contrast to the consequences of M<sub>2</sub>/M<sub>3</sub> mACh receptor coexpression for the regulation of ERK activity, the profile of JNK activation in CHO-m2m3 cells showed only modest differences from the CHO-m3 cell-line. Although constitutively active G<sub>iα</sub> proteins can be shown to stimulate JNK activity (Yamauchi *et al.*, 2000), in our hands M<sub>2</sub> mACh receptor activation did not stimulate JNK activity in CHO cells and therefore the lack of M<sub>2</sub>/M<sub>3</sub> interaction to promote JNK activation was anticipated.

The observation of an altered duration of ERK activation in the receptor coexpressing cell-line may be particularly significant, as it has been shown that how well receptor-mediated ERK activation is maintained markedly affects the outcome with respect to cell fate (Marshall, 1995). Thus, a number of well-characterized examples now exist to show that the longevity of ERK activation, rather than simply the magnitude of the response, determines cellular decision-making with respect to processes such as proliferation, cell growth and transformation (Tombs *et al.*, 1998; Orsini *et al.*, 1999; Murphy *et al.*, 2002). Therefore, if the increased agonist sensitivity and responsiveness, together with a more sustained pattern of ERK activation, are general features of cells coexpressing M<sub>2</sub>/M<sub>3</sub> mACh receptors this may be of particular physiological significance.

#### G<sub>q/11</sub> and G<sub>i/o</sub> involvement in M<sub>3</sub> mACh receptor-ERK signalling

Unexpected results were obtained with respect to ERK activation profiles generated in CHO-m2m3 cells following PTx pretreatment. It had been anticipated that toxin ablation of M<sub>2</sub> mACh receptor-G<sub>i/o</sub> signalling would result in agonist concentration–effect curves that overlay those obtained in CHO-m3 cells; however, while the maximum responsiveness decreased to levels typically seen in CHO-m3 cells (i.e. from approx 30-fold down to 10–15 fold), no rightward shift in the concentration-dependency was observed. Interestingly, a partial explanation for these data was provided by experiments where CHO-m3 cells were PTx-treated. Under these conditions, the concentration–effect curve for the agonist-stimulated increase in ERK activity was dramatically left-shifted. Taken together these data suggest that under normal conditions M<sub>3</sub> mACh receptors couple to both G<sub>q/11</sub> and G<sub>i/o</sub>

proteins and inactivation of the G<sub>i/o</sub> protein subpopulation appears to result in a much greater sensitivity (approx 100-fold) to agonist with respect to ERK activation. These data contrast with an elegant previous study by Blaukat *et al.* (2000) who demonstrated that efficient ERK activation by B<sub>2</sub> bradykinin, and M<sub>1</sub> and M<sub>3</sub> mACh receptors is dependent on cooperation between G<sub>q/11</sub>α and G<sub>i/o</sub>α signals in HEK293T cells.

We have previously shown that M<sub>3</sub> mACh receptors can couple to G<sub>i/o</sub> proteins in CHO cell membrane preparations by Gα-subtype-specific immunoprecipitation of G protein-[<sup>35</sup>S]-GTPγS complexes (Akam *et al.*, 2001). Using the same technique here, we have shown that PTx pretreatment did not affect receptor-G<sub>q/11</sub> coupling in CHO-m3 cells, and while MCh stimulated an increased maximal yield of G<sub>q/11</sub>α protein-[<sup>35</sup>S]-GTPγS complexes in CHO-m2m3 cell membranes, the concentration dependency of this stimulation was unaffected by G<sub>i/o</sub> inactivation. Thus, the observed effects of PTx on receptor-G<sub>q/11</sub> coupling in membranes derived from CHO-m3 and -m2m3 cells provide little insight into what may underlie the effects seen at the level of ERK regulation.

How is it possible to rationalize a situation where M<sub>2</sub> mACh receptor stimulation *per se* stimulates a robust and entirely PTx-sensitive ERK activity, while M<sub>3</sub> mACh receptor stimulation also appears to recruit a G<sub>i/o</sub> component, but in this case to attenuate the G<sub>q/11</sub>-driven ERK response? Furthermore, in the CHO-m2m3 cell-line costimulation of the M<sub>2</sub>-receptor must either suppress or overcome any G<sub>i/o</sub> protein component stimulated by the M<sub>3</sub>-receptor such that M<sub>2</sub>/M<sub>3</sub> mACh receptor coactivation results in the marked leftward curve shift and increased responsiveness. At present, we can only speculate on the mechanism(s) that underlies the data

presented here. One possibility is that distinct G<sub>i/o</sub>α protein subpopulations are activated by M<sub>2</sub> and M<sub>3</sub> receptors that respectively mediate stimulatory or inhibitory effects on the pathways regulating ERK activity. There is some evidence for this in the CHO cell-lines used here (Dell'Acqua *et al.*, 1993; Akam *et al.*, 2001) and in other systems (Migeon *et al.*, 1995). In addition, it is possible that M<sub>2</sub> and M<sub>3</sub> receptors may facilitate the release of distinct G<sub>i/o</sub>-derived βγ-subunit combinations, or there may be micro-compartmentation of mACh receptor access to G<sub>i/o</sub> pools (Gudermann *et al.*, 1996; Albert & Robillard, 2002).

In summary, we have demonstrated a number of interactions between M<sub>2</sub> and M<sub>3</sub> mACh receptor signalling pathways that are unlikely to result from simple additivity between convergent signalling events. In particular, we report that coactivation of M<sub>2</sub> and M<sub>3</sub> mACh receptors in a CHO cell background results in a synergistic activation of ERK where both the sensitivity and responsiveness to agonist stimulation are increased. These data raise the question of whether ERK activation is similarly facilitated in tissues coexpressing these mACh receptor populations.

We thank Roche Bioscience (Palo Alto, U.S.A.) for financial support to D.C.H. and P.D.R. We gratefully acknowledge the work of Donna K. Boxall and Barbara Keys in helping to establish the CHO-m2m3 clonal cell-lines. We thank Professor C. Melchiorre (University of Bologna, Italy) for the gift of tripitramine, Dr Noel Davies for providing expert advice on the curve-fitting analysis. Finally, we would like to express our gratitude to Professor Steve Nahorski (University of Leicester), and Drs Richard Eglén, Anthony Ford and Don Daniels (Roche Bioscience, Palo Alto, USA) for their help, advice and encouragement during this project.

## References

- AKAM, E.C., CHALLISS, R.A.J. & NAHORSKI, S.R. (2001). G<sub>q/11</sub> and G<sub>i/o</sub> activation profiles in CHO cells expressing human muscarinic receptors: dependence on agonist as well as receptor-subtype. *Br. J. Pharmacol.*, **132**, 950–958.
- ALBERT, P.R. & ROBILLARD, L. (2002). G protein specificity: traffic direction required. *Cell. Signal.*, **14**, 407–418.
- BATCHELOR, A.M. & GARTHWAITE, J. (1997). Frequency detection and temporally dispersed synaptic signal association through a metabotropic glutamate receptor pathway. *Nature*, **385**, 74–77.
- BLAUKAT, A., BARAC, A., CROSS, M.J., OFFERMANN, S. & DIKIC, I. (2000). G protein-coupled receptor-mediated mitogen-activated protein kinase activation through cooperation of G<sub>q</sub> and G<sub>α</sub> signals. *Mol. Cell. Biol.*, **20**, 6837–6848.
- BONNER, T.L., BUCKLEY, N.J., YOUNG, A.C. & BRANN, M.R. (1987). Identification of a family of muscarinic acetylcholine receptor genes. *Science*, **237**, 527–532.
- BROWN, B.L., ALBANO, J.D.M., ELKINS, R.P., SGHERZI, A.M. & TAMPION, W. (1971). A simple and sensitive saturation assay method for the measurement of adenosine 3',5'-cyclic monophosphate. *Biochem. J.*, **121**, 561–563.
- BUDD, D.C., WILLIAMS, G.B., MCDONALD, J.E. & TOBIN, A.B. (2001). Phosphorylation of the G<sub>q/11</sub>-coupled M<sub>3</sub>-muscarinic receptor is involved in receptor activation of the ERK-1/2 mitogen-activated protein kinase pathway. *J. Biol. Chem.*, **276**, 4581–4587.
- BURACK, W.R. & SHAW, A.S. (2000). Signal transduction: hanging on a scaffold. *Curr. Opin. Cell Biol.*, **12**, 211–216.
- BURFORD, N.T. & NAHORSKI, S.R. (1996). Muscarinic m1 receptor-stimulated adenylate cyclase activity in Chinese hamster ovary cells is mediated by G<sub>α</sub> and is not a consequence of phosphoinositidase C activation. *Biochem. J.*, **315**, 883–888.
- CAULFIELD, M.P. & BIRDSALL, N.J.M. (1998). IUPHAR XVII. Classification of muscarinic acetylcholine receptors. *Pharmacol. Rev.*, **50**, 279–290.
- CHALLISS, R.A.J. & BLANK, J.L. (1997). Muscarinic acetylcholine receptor signalling pathways in smooth muscle. In: *Muscarinic Receptor Subtypes in Smooth Muscle*. ed. Eglén, R.M. pp. 39–86. Boca Raton: CRC Press, Inc.
- CHALLISS, R.A.J., BATTY, I.H. & NAHORSKI, S.R. (1988). Mass measurements of inositol 1,4,5-trisphosphate in rat cerebral cortex slices using a radioreceptor assay: effects of neurotransmitters and depolarization. *Biochem. Biophys. Res. Commun.*, **157**, 684–691.
- CHAN, J.S.C., LEE, J.W.M., HO, M.K.C. & WONG, Y.H. (2000). Preactivation permits subsequent stimulation of phospholipase C by Gi-coupled receptors. *Mol. Pharmacol.*, **57**, 700–708.
- CHOPPIN, A., STEPAN, G.J., LOURY, D.N., WATSON, N. & EGLÉN, R.M. (1999). Characterization of the muscarinic receptor in isolated uterus of sham-operated and ovariectomized rats. *Br. J. Pharmacol.*, **127**, 1551–1558.
- CRESPO, P., XU, N., SIMONDS, W.F. & GUTKIND, J.S. (1994). Ras-dependent activation of MAP kinase pathway mediated by G protein βγ-subunits. *Nature*, **369**, 418–420.
- DELL'ACQUA, M.L., CARROLL, R.C. & PERALTA, E.G. (1993). Transfected m2 muscarinic acetylcholine receptors couple to G<sub>α2</sub> and G<sub>α3</sub> in Chinese hamster ovary cells. *J. Biol. Chem.*, **268**, 5676–5685.
- DHANASEKARAN, N., HEASLEY, L.E. & JOHNSON, G.L. (1995). G protein-coupled receptor systems involved in cell growth and oncogenesis. *Endocrine Rev.*, **16**, 259–270.
- DICKENSON, J.M., BLANK, J.L. & HILL, S.J. (1998). Human adenosine A<sub>1</sub> receptor and P2Y<sub>2</sub>-purinoceptor-mediated activation of the mitogen-activated protein kinase cascade in transfected CHO cells. *Br. J. Pharmacol.*, **124**, 1491–1499.

- DUMONT, J.E., DREMIER, S., PIRSON, I. & MAENHAUT, C. (2002). Cross signalling, cell specificity, and physiology. *Am. J. Physiol.*, **283**, C2 – C28.
- EGLER, R.M., HEGDE, S.S. & WATSON, N. (1996). Muscarinic receptor subtypes and smooth muscle function. *Pharmacol. Rev.*, **48**, 531 – 565.
- EGLER, R.M., REDDY, H., WATSON, N. & CHALLISS, R.A.J. (1994). Muscarinic acetylcholine receptor subtypes in smooth muscle. *Trends Pharmacol. Sci.*, **15**, 114 – 119.
- FAGAN, K.A., MONS, N. & COOPER, D.M.F. (1998). Dependence of the Ca<sup>2+</sup>-inhibitable adenylyl cyclase of C6-2B glioma cells on capacitative Ca<sup>2+</sup> entry. *J. Biol. Chem.*, **273**, 9297 – 9305.
- GUDERMANN, T., GROSSE, R. & SCHULTZ G. (2000). Contribution of receptor/G protein signaling to cell growth and transformation. *Naunyn-Schmiedeberg's Arch. Pharmacol.*, **361**, 345 – 362.
- GUDERMANN, T., KALKBRENNER, F. & SCHULTZ, G. (1996). Diversity and selectivity of receptor-G protein interaction. *Annu. Rev. Pharmacol. Toxicol.*, **36**, 429 – 459.
- GUTKIND, J.S. (1998). The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. *J. Biol. Chem.*, **273**, 1839 – 1842.
- HEGDE, S.S., CHOPPIN, A., BONHAUS, D., BRIAUD, S., LOEB, M., MOY, T.M., LOURY, D. & EGLER, R.M. (1997). Functional role of M<sub>2</sub> and M<sub>3</sub> muscarinic receptors in the urinary bladder of rats *in vitro* and *in vivo*. *Br. J. Pharmacol.*, **120**, 1409 – 1418.
- KIM, J.Y., YANG, M.S., OH, C.D., KIM, K.T., HA, M.J., KANG, S.S. & CHUN, J.S. (1999). Signalling pathway leading to an activation of mitogen-activated protein kinase by stimulating M<sub>3</sub> muscarinic receptor. *Biochem. J.*, **337**, 275 – 280.
- KURACHI, Y. (1995). G protein regulation of cardiac muscarinic potassium channel. *Am. J. Physiol.*, **269**, C821 – C830.
- LOPEZ-ILASACA, M., CRESPO, P., PELLICI, P.G., GUTKIND, J.S. & WETZKER, R. (1997). Linkage of G protein-coupled receptors to the MAPK signalling pathway through PI 3-kinase  $\gamma$ . *Science*, **275**, 394 – 397.
- MARSHALL, C.J. (1995). Specificity of receptor tyrosine kinase signalling: transient versus sustained extracellular signal-regulated kinase activation. *Cell*, **80**, 179 – 185.
- MATSUI, M., MOTOMURA, D., KARASAWA, H., FUJIKAWA, T., JIANG, J., KOMIYA, Y., TAKAHASHI, S. & TAKETO, M.M. (2000). Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M<sub>3</sub> subtype. *Proc. Natl. Acad. Sci. U.S.A.*, **97**, 9579 – 9584.
- MELCHIORRE, C., BOLOGNESI, M.L., CHIARINI, A., MINARINI, A. & SPAMPINATO, S. (1993). Synthesis and biological activity of some methoctramine-related tetraamines bearing a 11-acetyl-5,11-dihydro-6H-pyrido[2,3-b][1,4]-benzodiazepine-6-one moiety as anti-muscarinics: a second generation of highly selective M<sub>2</sub> muscarinic receptor antagonists. *J. Med. Chem.*, **36**, 3734 – 3737.
- MIGEON, J.C., THOMAS, S.L. & NATHANSON, N.M. (1995). Differential coupling of m2 and m4 muscarinic receptors to inhibition of adenylyl cyclase by G<sub>i</sub> $\alpha$  and G<sub>o</sub> $\alpha$  subunits. *J. Biol. Chem.*, **270**, 16070 – 16074.
- MITCHELL, F.M., RUSSELL, M. & JOHNSON, G.L. (1995). Differential calcium dependence in the activation of c-jun kinase and mitogen-activated protein kinase by muscarinic acetylcholine receptors in rat 1a cells. *Biochem. J.*, **309**, 381 – 384.
- MURPHY, L.O., SMITH, S., CHEN, R.-H., FINGAR, D.C. & BLENIS, J. (2002). Molecular interpretation of ERK signal duration by immediate early gene products. *Nat. Cell. Biol.*, **4**, 556 – 564.
- OFFERMANN, S., WIELAND, T., HOMANN, D., SANDMANN, J., BOMBIEN, E., SPICHER, K., SCHULTZ, G. & JAKOBS, K.-H. (1994). Transfected muscarinic acetylcholine receptors selectively couple to G<sub>i</sub>-type proteins and G<sub>q/11</sub>. *Mol. Pharmacol.*, **45**, 890 – 898.
- ORSINI, M.J., KRYMSKAYA, V.P., ESZTERHAS, A.J., BENOVIĆ, J.L., PANETTIERI, R.A. & PENN, R.B. (1999). MAPK superfamily activation in human airway smooth muscle: mitogenesis requires prolonged p42/p44 activation. *Am. J. Physiol.*, **277**, L479 – L488.
- PAWSON, T. & SAXTON, T.M. (1999). Signaling networks – do all roads lead to the same genes?. *Cell*, **97**, 675 – 678.
- QUITTERER, U. & LOHSE, M.J. (1999). Crosstalk between G $\alpha_i$ - and G $\alpha_q$ -coupled receptors is mediated by G $\beta\gamma$  exchange. *Proc. Natl. Acad. Sci. U.S.A.*, **96**, 10626 – 10631.
- RHEE, S.G. (2001). Regulation of phosphoinositide-specific phospholipase C. *Annu. Rev. Biochem.*, **70**, 281 – 312.
- SAMBROOK, J., FRITSCH, E.F. & MANIATIS, T. (1989). *Molecular Cloning, a Laboratory Manual*. pp. 16.32 – 16.40. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
- SAWYER, G.W. & EHLERT, F.J. (1999). Muscarinic M<sub>3</sub> receptor inactivation reveals a pertussis toxin-sensitive contractile response in the guinea pig colon: evidence for M<sub>2</sub>/M<sub>3</sub> receptor interactions. *J. Pharmacol. Exp. Ther.*, **289**, 464 – 476.
- SCHAEFFER, H.J. & WEBER, M.J. (1999). Mitogen-activated protein kinases: specific messages from ubiquitous messengers. *Mol. Cell. Biol.*, **19**, 2435 – 2444.
- SELBIE, L.A. & HILL, S.J. (1998). G protein-coupled receptor cross-talk: the fine-tuning of multiple receptor-signalling pathways. *Trends Pharmacol. Sci.*, **19**, 87 – 93.
- SLACK, B.E. (2000). The m3 muscarinic acetylcholine receptor is coupled to mitogen-activated protein kinase via protein kinase C and epidermal growth factor receptor kinase. *Biochem. J.*, **348**, 381 – 387.
- STENGEL, P.W., GOMEZA, J., WESS, J. & COHEN, M.L. (2000). M<sub>2</sub> and M<sub>4</sub> receptor knockout mice: muscarinic receptor function in cardiac and smooth muscle *in vitro*. *J. Pharmacol. Exp. Ther.*, **292**, 877 – 885.
- STENGEL, P.W., YAMADA, M., WESS, J. & COHEN, M.L. (2002). M<sub>3</sub>-receptor knockout mice: muscarinic receptor function in atria, stomach fundus, urinary bladder, and trachea. *Am. J. Physiol.*, **282**, R1443 – R1449.
- SUNAHARA, R.K., DESSAUER, C.W. & GILMAN, A.G. (1996). Complexity and diversity of mammalian adenylyl cyclases. *Annu. Rev. Pharmacol. Toxicol.*, **36**, 461 – 480.
- SWEATT, J.D. (2001). The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. *J. Neurochem.*, **76**, 1 – 10.
- TOBIN, A.B. & NAHORSKI, S.R. (1993). Rapid agonist-mediated phosphorylation of m3-muscarinic receptors revealed by immunoprecipitation. *J. Biol. Chem.*, **268**, 9817 – 9823.
- TOMBES, R.M., AUER, K.L., MIKKELSEN, R., VALERIE, K., WY-MANN, M.P., MARSHALL, C.J., MCMAHON, M. & DENT, P. (1998). The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic. *Biochem. J.*, **330**, 1451 – 1460.
- WANG, Y.X., DHULIPALA, D.K., LI, L., BENOVIĆ, J.L. & KOTLIK-OFF, M.I. (1999). Coupling of M<sub>2</sub> muscarinic receptors to membrane ion channels via phosphoinositide 3-kinase- $\gamma$  and atypical protein kinase C. *J. Biol. Chem.*, **274**, 13859 – 13864.
- WESS, J. (1993). Molecular basis of muscarinic acetylcholine receptor function. *Trends Pharmacol. Sci.*, **14**, 308 – 313.
- WESSLER, I., KIRKPATRICK, C.J. & RACKE, K. (1998). Non-neuronal acetylcholine, a locally acting molecule, widely distributed in biological systems: expression and function in humans. *Pharmacol. Ther.*, **77**, 59 – 79.
- WINITZ, S., RUSSELL, M., QUIAN, N.X., GARDNER, A., DWYER, L. & JOHNSON, G.L. (1993). Involvement of Ras and Raf in the G<sub>i</sub>-coupled acetylcholine muscarinic m2 receptor activation of mitogen-activated protein (MAP) kinase kinase and MAP kinase. *J. Biol. Chem.*, **268**, 19196 – 19199.
- WONG, M.P.M., COOPER, D.M.F., YOUNG, K.W. & YOUNG, J.M. (2000). Characteristics of the Ca<sup>2+</sup>-dependent inhibition of cyclic AMP accumulation by histamine and thapsigargin in human U373 MG astrocytoma cells. *Br. J. Pharmacol.*, **130**, 1021 – 1030.
- WYLIE, P.G., CHALLISS, R.A.J. & BLANK, J.L. (1999). Regulation of extracellular-signal regulated kinase and c-Jun N-terminal kinase by G-protein-linked muscarinic acetylcholine receptors. *Biochem. J.*, **338**, 619 – 628.
- YAMAUCHI, J., KAWANO, T., NAGAO, M., KAZIRO, Y. & ITOH, H. (2000). G $\gamma$ -dependent activation of c-Jun N-terminal kinase in human embryonal kidney 293 cells. *J. Biol. Chem.*, **275**, 7633 – 7640.
- ZHOLOS, A.V. & BOLTON, T.B. (1997). Muscarinic receptor subtypes controlling the cationic current in guinea-pig ileal smooth muscle. *Br. J. Pharmacol.*, **122**, 885 – 893.

(Received November 21, 2002

Revised December 18, 2002

Accepted January 6, 2003)